Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Anthera's Blisibimod Positive in Phase II Extension Study
by Zacks Equity Research
Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.
Roche's Gazyva Gets Priority Review for Follicular Lymphoma
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.
J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III
by Zacks Equity Research
J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
by Zacks Equity Research
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
Novartis Announces Positive Data on Cardiovascular Drug
by Zacks Equity Research
Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).
Kamada (KMDA) Gets FDA Approval for Rabies Vaccine
by Zacks Equity Research
Kamada Ltd. (KMDA) and partner Kedrion Biopharma and announced that FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection.
Will Endo (ENDP) Continue to Disappoint Investors in 2017?
by Zacks Equity Research
Endo (ENDP) a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations.
Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate
by Zacks Equity Research
Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.
Novartis (NVS) Receives EC Approval for Breast Cancer Drug
by Zacks Equity Research
Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.
Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data
by Zacks Equity Research
Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
BioLineRx Moves a Regulatory Submission for BL-8040 Trial
by Zacks Equity Research
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
Alkermes Initiates Rolling Submission of Depression Drug
by Zacks Equity Research
Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak
by Zacks Equity Research
Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
by Zacks Equity Research
Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss
by Zacks Equity Research
Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.
Catalyst (CPRX) Posts Narrower than Expected Loss in Q2
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View
by Zacks Equity Research
Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.